HomeCompareGRCL vs VICI

GRCL vs VICI: Dividend Comparison 2026

GRCL yields 19.51% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $895.4K in total portfolio value· pulled ahead in Year 6
10 years
GRCL
GRCL
● Live price
19.51%
Share price
$10.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.9K
Annual income
$6,394.90
Full GRCL calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — GRCL vs VICI

📍 VICI pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRCLVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRCL + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRCL pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRCL
Annual income on $10K today (after 15% tax)
$1,658.54/yr
After 10yr DRIP, annual income (after tax)
$5,435.67/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $510,834.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRCL + VICI for your $10,000?

GRCL: 50%VICI: 50%
100% VICI50/50100% GRCL
Portfolio after 10yr
$518.5K
Annual income
$306,885.51/yr
Blended yield
59.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

GRCL
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$6.00
-41.5% upside vs current
Range: $6.00 — $6.00
Altman Z
1.5
Piotroski
3/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRCL buys
0
VICI buys
0
No recent congressional trades found for GRCL or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRCLVICI
Forward yield19.51%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$70.9K$966.2K
Annual income after 10y$6,394.90$607,376.13
Total dividends collected$39.8K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$6.00$31.60

Year-by-year: GRCL vs VICI ($10,000, DRIP)

YearGRCL PortfolioGRCL Income/yrVICI PortfolioVICI Income/yrGap
1$12,651$1,951.22$11,361$941.49+$1.3KGRCL
2$15,844$2,307.04$13,320$1,481.32+$2.5KGRCL
3$19,653$2,700.22$16,284$2,405.01+$3.4KGRCL
4$24,159$3,130.30$21,040$4,071.78+$3.1KGRCL
5$29,447$3,596.27$29,209$7,285.49+$238.00GRCL
6← crossover$35,604$4,096.58$44,443$14,006.51$8.8KVICI
7$42,726$4,629.21$75,822$29,512.55$33.1KVICI
8$50,908$5,191.72$148,733$69,726.75$97.8KVICI
9$60,253$5,781.31$344,394$189,413.75$284.1KVICI
10$70,866$6,394.90$966,234$607,376.13$895.4KVICI

GRCL vs VICI: Complete Analysis 2026

GRCLStock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Full GRCL Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this GRCL vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRCL vs SCHDGRCL vs JEPIGRCL vs OGRCL vs KOGRCL vs MAINGRCL vs NNNGRCL vs EPRTGRCL vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.